Home/Pipeline/ARV-102

ARV-102

Parkinson's Disease

Phase 1Active

Key Facts

Indication

Parkinson's Disease

Phase

Phase 1

Status

Active

Company

Arvinas

About Arvinas

Arvinas is a leader in the field of targeted protein degradation, developing novel therapeutics through its proprietary PROTAC® platform. The company has achieved significant clinical validation, with its lead oncology asset, vepdegestrant, demonstrating efficacy in pivotal trials for breast cancer, and its neuroscience candidate, ARV-102, showing compelling early-stage proof-of-concept in Parkinson's disease. Arvinas's strategy combines internal R&D with strategic partnerships, such as its major collaboration with Pfizer, to advance a deep pipeline and solidify its position as a platform innovator and drug developer.

View full company profile

Therapeutic Areas

Oncology Neurology

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active